GSK (GSK +0.1%) showcases its drugs pipeline to investors and analysts, saying it expects to...

|By:, SA News Editor

GSK (GSK +0.1%) showcases its drugs pipeline to investors and analysts, saying it expects to receive Phase III trial results of up to 14 treatments over the next two years, including for heart medicine darapladib and cancer vaccine MAGE-A3. GSK's strategy is to develop a broader array of drugs, some of which could be blockbusters, although others have smaller commercial potential. (Presentation)